Navigation Links
Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
Date:2/26/2009

    - Quarter Highlighted by Regulatory Approval of Once-Daily Tramadol in
    the U.S and FDA Acceptance of NDA for Novel Treatment for Depression -

LAVAL, QC, Feb. 26 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the fourth quarter and year ended December 31, 2008. All figures are in Canadian dollars unless otherwise stated.

"With our first product about to be rolled out in the world's largest pharmaceutical market, our second under consideration for regulatory approval by the FDA and our third undergoing a Phase III study, 2009 will be an eventful year with a series of value-driving milestones." said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc.

    Labopharm's key milestone events in 2009 include:
      -  Launch of its once-daily tramadol product in the U.S. during the
         second quarter;
      -  The PDUFA date for its novel trazodone formulation on July 18; and
      -  Results of the Phase III clinical trial for its twice-daily
         tramadol-acetaminophen formulation during the first half of the
         year.

Financial Summary

Revenue from product sales of Labopharm's once-daily tramadol for the fourth quarter of fiscal 2008 increased to $3.3 million from $1.6 million for the fourth quarter of fiscal 2007. Adjusted gross margin for the fourth quarter of fiscal 2008 increased to 51.8% from 43.5% for the fourth quarter of fiscal 2007, primarily due to higher average selling prices. Research and development expenses, net of research and development tax credits, for the fourth quarter of fiscal 2008 were $5.2 million compared with $6.3 million for the fourth quarter of fiscal 2007. Selling, general and administrative expenses for the fourth quarter of fiscal 2008, were $10.6
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
2. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
3. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
4. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
5. Labopharm Comments on Recent Trading Activity
6. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
7. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
8. Labopharm announces change to Board of Directors
9. Labopharm Reports Results for Third Quarter Fiscal 2008
10. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
11. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 02, 2015 Specialty Technical ... compliance and risk solutions , and Radar today ... management effectiveness gap-improvement program. , All organizations need ... on objectives. Organizations not only assess and treat ... to do this (risk managing) thereby embedding these ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Lynn Lester as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... honor Lynn Lester with this prestigious award,” said NAPW ...
(Date:6/1/2015)... 02, 2015 The National Association ... as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in safety, environment, health ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Lourinda with this important honor,” said ...
(Date:6/1/2015)... June 02, 2015 The National ... Tansey as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in mental health. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor," said NAPW President Star Jones. ...
(Date:6/1/2015)... 2015 Carson Energy also announced they ... IRA transactions. AdvantaIRA Trust, LLC is the country’s largest ... to fund positions using IRA’s does 2 things:, 1. ... project, even if there current cash position will not ... source for Carson and their investors to be able ...
Breaking Medicine News(10 mins):Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2
... five elderly Americans living on their own takes a ... and illness. According to the report, more than 21% ... least one of these 33 potentially inappropriate medications in ... people should always avoid, including certain sedatives, long-acting drugs ...
... amounts of heart tissue is as safe for babies as ... radiofrequency catheter ablation (RFCA) treatment involves threading a catheter - ... of the heart which is struggling with an uncontrolled heartbeat, ... radiofrequency energy, similar to microwave heat, is used to destroy ...
... everything from heartburn to impotence have prompted one in eight ... retain critical information about the drug and possible side effects. ... Food and Drug Administration set up rules and made them ... have a considerable effect -- nearly a third of adults ...
... Group therapy can help breast cancer patients feel better, but ... therapy in addition to their medical treatment lived an average// ... therapy did not live any longer than the 77 who ... did report less pain and emotional distress -- especially if ...
... pump up their physiques should know that many over-the-counter ... Many people who buy these supplements are getting ripped ... that they purchased in stores. They analyzed the products ... listed on the label were actually contained in the ...
... and Drugs Department is beginning to bare its fangs ... offence under the Indian Drugs and Cosmetics Act, 1940. ... this common practice jeopardise the health of the masses ... drugs -- it also endangers the job prospects of ...
Cached Medicine News:
(Date:6/1/2015)... JOLLA, Calif. , June 1, 2015 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and ... that Kleanthis G. Xanthopoulos , Ph.D. has ... as a member of Regulus, Board of Directors, ... biotechnology industry.  Paul Grint, M.D., who previously served ...
(Date:6/1/2015)... DURHAM, N.C. , June 1, 2015  bioMérieux, ... vitro diagnostics, has been invited to join the ... of antibiotic use in the U.S. as a means ... various sectors, will gather tomorrow, June 2, 2015, to ... next five years to slow the emergence of antibiotic-resistant ...
(Date:6/1/2015)... June 1, 2015 Select Medical Holdings Corporation ... Corporation, a joint venture that Select Medical Corporation ("Select") ... completed its previously announced acquisition of Concentra Inc.  Cressey ... venture. About Select Medical Corporation ... hospitals and outpatient rehabilitation clinics in the ...
Breaking Medicine Technology:Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 2bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... Dec. 22, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings ... 910801.TW), China,s leading integrated healthcare enterprise, today announced that ... market, accumulating a total of 36,976,000 shares in December ... shares at a weighted average price of HK$0.83 per ...
... question confronting neuroscientists and computer vision researchers alike is how ...  Introspectively, we know that the human brain solves this problem ... know what it is. But teaching a computer ... research published this fall in the Public Library of ...
Cached Medicine Technology:Golden Meditech Further Repurchases Shares 2Do You See What I See: Scientists Model Brain Structure To Help Computers Recognize Objects 2Do You See What I See: Scientists Model Brain Structure To Help Computers Recognize Objects 3Do You See What I See: Scientists Model Brain Structure To Help Computers Recognize Objects 4
... into the punctal opening to block tear ... long-term relief of dry eye symptoms, and ... its own natural tears:, Low-profile cap ... of cap design facilitates easy removal with ...
Extended Duration absorbable plugs are designed to provide patient comfort for up to 3 months. This long lasting plug is effective and economical for transient dry eye symptoms following surgery. Ext...
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
Medicine Products: